Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Pharmacokinetics of Vonafexor in Healthy Volunteers and NASH Patients
NCT03976687Phase 1Completed
- Sponsor
- ENYO Pharma
- Start
- Jun 2019
- Primary completion
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vonafexor in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by ENYO Pharma. Primary endpoints: Maximum plasma concentration, Time to reach maximum concentration and 2 more. Started Jun 2019; status: completed.
02
Drugs
vonafexor
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03976687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03976687.